RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation

        Rishi Agarwal,Kimberly Koenig,Eric Rohren,Vivek Subbiah 한국유방암학회 2014 Journal of breast cancer Vol.17 No.3

        Metaplastic breast cancer (MpBC) is an extremely rare breastcancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, noveltargeted therapies should be explored. Herein, we report theclinical course of a 59-year-old African American woman withMpBC with a PIK3CA mutation in codon 545, exon 10 (GAG toAAG; p.Glu545Lys) and a TP53 mutation in codon 286, exon 8(GAA to AAA; p.Glu286Lys). The same mutations were observedin the primary and secondary sites. The patient wastreated with a molecularly matched therapy using a combinedantiangiogenic and mammalian target of rapamycin kinase inhibitorstrategy that included liposomal doxorubicin, bevacizumab,and temsirolimus. Partial remission was achieved. Inthis report, the scientific rationale underlying the activity of thiscombination was explored. In conclusion, patients may benefitfrom being offered molecular profiling early during the course ofthe disease to receive a therapy guided accordingly.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼